NasdaqCM · Biotechnology

BioLineRx (BLRX)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered+718.5%

$23.00 average target

$2.81+0.05 (+1.8%)Latest market snapshot · Yahoo Finance

Market cap$12.3M

Cash$17.4M

Quarterly burn$2.3M

Pipeline assets6

Short float3.1%

Clinical portfolio

BioLineRx Drug Pipeline

Showing 1 of 6

Asset	Indication	Stage	Milestone	Signals ?
Motixafortide (BL-8040) w/ cemiplimab	Pancreatic cancer	Phase 2b	Dec 31, 2026	Mgmt interest

Continue with BioPharma ProUnlock 5 additional programs and complete development details.

Unlock Pro

Upcoming milestones

BLRX Catalyst Timeline

1 currently tracked

Dec 31, 2026

Motixafortide (BL-8040) w/ cemiplimab

Phase 2b

Company profile

About BioLineRx

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.